Related Experiment Video
Updated: Mar 25, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Platelet Inhibitors
Megan M Shifrin1, S Brian Widmar2
1Vanderbilt University School of Nursing, 461 21st Avenue South, 382 Frist Hall, Nashville, TN 37240, USA.
Insights
Platelet-inhibiting medications are crucial for acute coronary syndrome but lack a specific reversal agent. Platelet transfusions may help manage bleeding after their use.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Antithrombotic medications are standard for acute coronary syndrome (ACS) management.
- Platelet function (adhesion, activation, aggregation) is key to thrombosis.
- Platelet-inhibiting drugs target these functions to reduce clot formation.
Purpose of the Study:
- To review the role of platelet inhibitors in ACS.
- To highlight the challenge of managing bleeding complications.
- To discuss current strategies for reversing platelet inhibition.
Main Methods:
- Literature review of antithrombotic therapies in ACS.
- Analysis of platelet function and inhibition mechanisms.
- Examination of bleeding management protocols.
Main Results:
- Platelet inhibitors effectively reduce thrombosis in ACS.
- Active bleeding is a contraindication for these drugs.
- No specific reversal agent currently exists for platelet inhibitors.
Conclusions:
- Platelet inhibitors are vital in ACS but pose bleeding risks.
- Management of bleeding often relies on supportive measures.
- Platelet transfusion is a potential option for active bleeding post-inhibition.
Abstract:
Antithrombotic medications have become standard of care for management of acute coronary syndrome. Platelet adhesion, activation, and aggregation are essential components of platelet function; platelet-inhibiting medications interfere with these components and reduce incidence of thrombosis. Active bleeding is a contraindication for administration of platelet inhibitors. There is currently no reversal agent for platelet inhibitors, although platelet transfusion may be used to correct active bleeding after administration of platelet inhibitors.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...